Pharmaceutical Technology Editors

MedImmune enters into an agreement to acquire the image analysis and data mining company.

AstraZeneca announced a partnership with Pharmacyclics and Janssen for combination trials of MEDI4736 (AstraZeneca) with Imbruvica (Pharmacyclics and Janssen) for the treatment of hematologic cancers.

An FDA warning letter to Hikma Pharmaceuticals cites violations of CGMP at its plant in Portugal that manufactures finished drugs.

Bristol-Myers Squibb entered into an agreement with Galecto Biotech AB to gain exclusive rights to TD139, a novel inhaled inhibitor of galectin-3 for the treatment of idiopathic pulmonary fibrosis.

LabCorp announced it will purchase contract research company Covance Inc. for approximately $6.1 billion in cash and stock.

Spectranetics announced that it acquired Covidien's drug-coated balloon platform, Stellarex, for $30 million.

Industry veteran Peter Bigelow to guide PBOA Board.

Sigma-Aldrich's custom manufacturing services business unit, SAFC, has launched a new protein quality supplement for biological drug production, including biosimilars.

SGS Life Science Services announced the completion of its Glasgow, UK testing facility for cell banks in biological medicines.

CDMO DPT Laboratories, a specialist in semi-solid and liquid dosage forms, announced that it has implemented a high-speed bottle-filling center at its San Antonio location.

The new Argos biomanufacturing facility in North Carolina will include automated production using the company's Arcelis technology.

Bristol-Myers Squibb announced that they have reached an agreement with F-star Alpha, giving BMS the exclusive option to acquire F-star's HER2-targeted breast and gastric cancer treatment.

GSK's investigational Ebola vaccine is in Phase I safety trials.

Johnson& Johnson is collaborating with WHO and others on clinical testing, development, production, and distribution of an Ebola vaccine.

Contract Packaging Resources issued a voluntary recall of naproxen sodium tablets because some cartons contain bottles of ibuprofen.

Ashland Specialty Ingredients opened a drug development and bioavailability enhancement facility in Wilmington, Delaware.

FDA approved a Cook Pharmica facility and a Patheon facility for manufacturing of Halozyme products.

AbbVie to pay Shire $1.635 billion break fee for terminating purchase agreement.

The agency recommends that companies developing drugs to treat Ebola apply for orphan drug designation.

Lilly announces the closure of its Guayama, Puerto Rico manufacturing facility amid continued investments at other plants.

The company submits an orphan drug application to FDA for its Cell-in-a-Box treatment for pancreatic cancer.

Sanofi Pasteur and Immune Design agree to jointly develop therapies through Phase II clinical trials.

BioReliance has introduced select in vitro ADME (absorption, distribution, metabolism and excretion) and toxicology testing services its service offering. The company#&39;s range of predictive assays use a novel suite of genetically modified cell lines created with CompoZr zinc finger nuclease (ZFN), a Sigma-Aldrich proprietary technology.

AbbVie sends Shire notice that it is reconsidering its offer recommendation.

The International Society for Pharmaceutical Engineering (ISPE) released its Drug Shortages Prevention Plan as part of an initiative to address drug shortage prevention due to manufacturing and quality issues.

Vetter's clinical manufacturing services continue to attract new business.

Hospira voluntary recalls certain lots of several LifeCare products due to potential for leakage.

The Pharmaceutical Research and Manufacturers of America released their 2014 Cancer Report that highlights the biopharmaceutical companies developing new medicines and vaccines used for the treatment of cancer.

A report from PhRMA highlights how drugs that failed in clinical trials are a crucial part of development for melanoma, lung cancer, and brain cancer.

IDT Biologika completes large-scale biologics finishing facility in Dessau, Germany.